

Congress of the United States
Washington, DC 20515

October 23, 2025

Mr. Geoffrey Chaiken
CEO
BlinkRx
1407 Broadway
Suite 1910
New York, NY 10018

Dear Mr. Chaiken:

We write to request information about the involvement of BlinkRx in the Direct-to-Consumer (DTC) platform the Trump Administration announced on September 30, called “TrumpRx.”¹ As the website for TrumpRx has not yet been launched and the Administration has not been transparent about how it will be designed or managed, we are conducting oversight of its development to determine whether this initiative will deliver meaningful savings to the American people for their prescription drugs and of other DTC platforms to evaluate potential conflicts of interest in their development and implementation.

Your company is one of many that allows customers to buy discounted prescription drugs directly from an online pharmacy.² In most cases, DTC platforms require patients to pay cash for drugs, meaning the patient cannot use their insurance coverage that the patient and/or their employer are paying for each month to help cover the costs. We seek information about the involvement, if any, of BlinkRx in the announcement of TrumpRx, development of the TrumpRx platform, or development of pharmaceutical companies’ platforms as a result of deals with the Trump Administration. This information is particularly important given the likelihood that members of the Trump family could benefit financially if BlinkRx were to be involved in the operation or implementation of TrumpRx, or receive additional business as a result of pharmaceutical companies’ deals with the Administration.³

BlinkRx announced the launch of “Operation Access Now” on August 7, 2025, which was about one week after President Trump sent letters to 17 pharmaceutical companies regarding their cooperation to lower drug costs through DTC platforms.⁴ “Operation Access Now” is a service that BlinkRx is promoting to pharmaceutical companies to establish DTC online

¹ *Trump Announces Deal with Pfizer to Lower Drug Prices, New ‘TrumpRx’ Website*, The Washington Post (Sept. 30, 2025).

² BlinkRx, *BlinkRx* (<https://www.blinkrx.com/>) (accessed Oct. 21, 2025).

³ *Trump Wants to Overhaul Drug Sales. A Company Tied to His Son Stands to Benefit.*, The Wall Street Journal (Oct. 7, 2025).

⁴ Business Wire, *BlinkRx Launches “Operation Access Now” to Accelerate and Scale Direct-to-Patient and Direct-to-Business Programs* (Aug. 7, 2025) (press release); *Trump Pressures 17 pharma CEOs to Cut US Drug Prices*, Reuters (July 31, 2025).

platforms that would allow them to comply with President Trump's demands.⁵ We also note that President Trump's son, Donald Trump, Jr., joined the BlinkRx Board of Directors earlier this year.⁶ Prior to his appointment, Mr. Trump, Jr.'s investment fund, 1789 Capital, led a \$140 million Series D financing round for BlinkRx. The timing of the BlinkRx announcement so closely following the Administration's outreach to the largest drug companies, and the involvement of President Trump's immediate family, raises questions about potential coordination, influence, and self-dealing.

The perception of orchestration between the Administration and BlinkRx is reinforced by BlinkRx's upcoming "Future of Pharmaceuticals" summit in December 2025, scheduled to take place at the Four Seasons Hotel in Washington, D.C. The event is expected to bring together pharmaceutical executives and senior officials in the Administration, including Health and Human Services Secretary Robert F. Kennedy, Jr. and Food and Drug Administration Commissioner Marty Makary. Multiple drugmakers have expressed concern that the summit's guest list and the company's proximity to the Administration could create an appearance of favor or solicitation. The compressed timeline between BlinkRx's launch of "Operation Access Now," the Administration's TrumpRx announcement, and this high-profile event invites additional scrutiny about whether these actions were coordinated to capitalize on actions undertaken by the Administration.

Pfizer, AstraZeneca, and Amgen have announced that customers will have access to their DTC platforms through TrumpRx.⁷ Part of agreements that have been made by the Trump Administration with Pfizer and AstraZeneca includes participation in the TrumpRx platform. This announcement came in exchange for a three-year delay on all tariffs President Trump threatened to impose on pharmaceutical products.⁸ There is no way to determine whether this platform and these pricing agreements will result in lower prices for consumers due to the Administration's complete lack of transparency about how such prices will be calculated and evaluated and what drugs are subject to the agreements. In fact, experts are already predicting that this action will not lower costs for consumers.⁹

"It's a lot of nothing," Craig Garthwaite, the director of the health-care program at Northwestern's Kellogg School of Management, [said]. "For most people, it will have very little effect on drug prices." Rena Conti, an economist and expert on the

⁵ *In Wake of Trump's Request for Direct Drug Sales, BlinkRx Debuts Off-The-Shelf DTC Platform for Pharmas*, Fierce Pharma (Aug. 12, 2025); *Trump Wants to Overhaul Drug Sales. A Company Tied to His Son Stands to Benefit.*, Wall Street Journal (Oct. 7, 2025).

⁶ PR Newswire, *BlinkRx Welcomes Donald Trump Jr. to Board of Directors* (Feb. 06, 2025) (press release).

⁷ Pfizer, *Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients* (Sept. 30, 2025) (press release); *Trump Announces a Deal on Drug Prices with AstraZeneca*, The New York Times (Oct. 10, 2025); Amgen, *Amgen makes Repatha® Available through AmgenNow, a Direct-To-Patient Program in the U.S.* (Oct. 6, 2025) (press release).

⁸ *Trump Announces 'TrumpRx' Site for Discounted Drugs and Deal with Pfizer to Lower Prices*, CNN (Sept. 30, 2025).

⁹ *President Announces TrumpRx Website for Drugs, and Pricing Deal with Pfizer*, NPR (Sept. 30, 2025).

biopharmaceutical industry who works at Boston University's Questrom School of Business, issued a similar assessment: "Top line is: it's a win for Pfizer, but not a win for American patients." Rather than radically restructuring drug pricing and distribution, the agreement amounted to "fiddling around the edges," she said.¹⁰

Wall Street, too, appears skeptical that such agreements are likely to deliver real savings for Americans. After the Pfizer announcement, one analyst said the agreement "represent[ed] a win" for the company and "would have a de minimis impact on their business going forward."¹¹

We are deeply concerned that this DTC platform, centralized through TrumpRx, will be yet another Administration action that enriches companies and industries with close ties to President Trump while doing nothing to reduce the excessively high costs of prescription drugs for Americans.

In order to better understand your company's involvement with these deals, we request answers to the questions below by November 6, 2025.

1. Did any individual from or on behalf of BlinkRx participate in discussions with any member of the Trump Administration regarding the letters sent to pharmaceutical companies in July 2025, which included demands for companies to develop DTC platforms? If so,

a. Who from or on behalf of BlinkRx and the Trump Administration participated in the discussion(s), and when did they occur?

b. What was the nature of the discussions?

c. Provide all related communications between BlinkRx employees or representatives and any member of the Trump Administration.

2. Did any individual from or on behalf of BlinkRx participate in discussions with any member of the Trump Administration regarding the September 30, TrumpRx announcement? If so,

a. Who from BlinkRx and the Trump Administration participated in the discussions, and when did they occur?

b. What was the nature of the discussions?

c. Provide all related communications between BlinkRx employees or representatives and any member of the Trump Administration.

¹⁰ *Donald Trump's Big Pharma Showdown Ends with a Whimper*, The New Yorker (Oct. 6, 2025).

¹¹ *Trump Claimed a Win on Drug Prices, but Big Pharma also Scored*, The Washington Post (Oct. 2, 2025).

3. Did any individual from or on behalf of BlinkRx participate in discussions with any member of the Trump Administration any other forthcoming prescription drug proposals?

a. Who from BlinkRx and the Trump Administration participated in the discussion(s), and when did they occur?

b. What was the nature of the discussions?

c. Provide all related communications between BlinkRx employees or representatives and any member of the Trump Administration.

4. Is BlinkRx currently providing services to any pharmaceutical companies through “Operation Access Now” to upgrade or develop DTC online platforms for the purpose of either connecting with TrumpRx in accordance with the Administration’s drug pricing initiative or otherwise complying with the terms of an agreement with the Administration? If so, specify which companies and what support they are receiving through “Operation Access Now.”

5. Is BlinkRx currently providing services to any United States government entity relating to TrumpRx?

6. Were any members of the BlinkRx Board of Directors involved in the development and announcement of “Operation Access Now?” If so, which member(s) and what was their involvement?

7. Has BlinkRx Director Donald Trump, Jr. ever recused himself from a board vote, discussion, or any other matter for any reason? If so, provide date(s), circumstances (board vote, discussion or other), and reason for recusal.

8. Will BlinkRx’s own DTC platform participate in TrumpRx by providing access to BlinkRx products through the new government platform? If so, provide all conditions of the participation agreement with the Administration.

Mr. Geoffrey Chaiken

October 23, 2025

Page 5

9. Please provide details about the upcoming “Futures of Pharmaceuticals” event, including the full agenda, attendee list, and all meeting materials. Did BlinkRx coordinate with any federal agencies in planning the summit?

If you have any questions about this request, please contact the Energy and Commerce Committee Democratic staff at (202) 225-2927, the Ways and Means Committee Democratic staff at (202) 225-3625, or the Finance Committee Democratic staff at (202) 224-4515.

Sincerely,



Frank Pallone, Jr.
Ranking Member
House Committee on Energy and
Commerce



Richard E. Neal
Ranking Member
House Committee on Ways and Means



Ron Wyden
Ranking Member
Senate Committee on Finance

cc: The Honorable Brett Guthrie
Chairman
House Committee on Energy and Commerce

The Honorable Jason Smith
Chairman
House Committee on Ways and Means

The Honorable Mike Crapo
Chairman
Senate Committee on Finance